AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ACTINOGEN MEDICAL LTD

0.059

0.000

Volume:1.07M

Turnover:63.16K

Market Cap:187.78M

PE:-11.93

High:0.060

Open:0.059

Low:0.059

Close:0.059

52wk High:0.065

52wk Low:0.019

Shares:3.18B

Float Shares:2.61B

Volume Ratio:0.18

T/O Rate:0.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.005

EPS(LYR):-0.005

ROE:-77.47%

ROA:-41.91%

PB:10.24

PE(LYR):-11.93

Loading ...

Overview Company News Filings

ASX Penny Stocks To Watch In December 2025

Simply Wall St.

BRIEF-Actinogen Randomizes 247th Patient in Xanamia Phase 2b/3 Alzheimer’s Trial

Final, 247TH Participant Randomized and Commences Treatment in Actinogen’s Xanamia Pivotal Phase 2B/3 Alzheimer’s Trial

THOMSON REUTERS

Actinogen Medical Ltd - Topline Final Results for Xanamia Trial in November 2026

THOMSON REUTERS

Actinogen Medical Starts Treatment of Patients in Alzheimer's Disease Trial

MT Newswires Live

Actinogen Medical Ltd-Acw CEO & CFO Present at Bell Potter Healthcare Conference

THOMSON REUTERS

Actinogen Medical Ltd-Acw Progress Update and Q&a Webinar Today

THOMSON REUTERS

Actinogen Medical Ltd-Advance Notice Acw Progress Update and Q&a Webinar

THOMSON REUTERS

Actinogen Medical Ltd-Acw September 2025 Quarterly Activity Report & Appendix 4C

THOMSON REUTERS

Actinogen Medical Ltd-Acw CEO Presents at Canaccord Drug & Device Conference

THOMSON REUTERS

BRIEF-Actinogen Medical Receives Initial A$5.5M Research And Development Tax Incentive Rebate

Actinogen Medical Ltd-Acw Receives Initial $5.5M R&D Tax Incentive Rebate

THOMSON REUTERS

Actinogen Medical Ltd - All Figures in AUD

THOMSON REUTERS

Actinogen Medical Ltd. Achieves FDA Agreement for Streamlined Development of Alzheimer's Drug Xanamem

Actinogen Achieves Agreement With the FDA in a Type C Meeting on the Manufacturing, Clinical and Nonclinical Activities Required for a Future US Marketing Approval of Xanamem for Alzheimer’s Disease

THOMSON REUTERS

Actinogen: FDA Agreed for Only One Additional, Pivotal Trial Using a Single 10 Mg Xanamem Dose Design VS. Placebo for Alzheimer's Trial

THOMSON REUTERS

Actinogen Medical Ltd - Meeting With European Medicines Agency for Alzheimer’s Disease Scheduled for 2026

THOMSON REUTERS

Actinogen Medical Ltd. Announces Successful Xanamem Tablet Formulation Trial in Alzheimer's Treatment, Confirms Target Exposures

Actinogen Says Trial Results Indicate Target Therapeutic Dose for Alzheimer's Treatment Candidate Clinical Program, Shares Rise 9%

MT Newswires Live

Actinogen Medical - FY Net Loss Attributable a$14.7 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ACW.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"ACW.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ACW.AU\",,,,,undefined,":{"symbol":"ACW.AU","market":"AU","secType":"STK","nameCN":"ACTINOGEN MEDICAL LTD","latestPrice":0.059,"timestamp":1766466720000,"preClose":0.059,"halted":0,"volume":1068139,"delay":0,"nameEN":"ACTINOGEN MEDICAL LTD","floatShares":2607880613,"shares":3182678236,"eps":-0.004944,"marketStatus":"Closed","change":0,"latestTime":"12-23 16:12:00 AEDT","open":0.059,"high":0.06,"low":0.059,"amount":63156,"amplitude":0.016949,"askPrice":0.06,"askSize":907537,"bidPrice":0.059,"bidSize":394311,"shortable":3,"etf":0,"ttmEps":-0.004944,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1766530800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.059,"openAndCloseTimeList":[[1766444400000,1766466000000]],"volumeRatio":0.184848,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ACW.AU\",,,,,undefined,":{"symbol":"ACW.AU","floatShares":2607880613,"roa":"-41.91%","roe":"-77.47%","lyrEps":-0.004944,"volumeRatio":0.184848,"shares":3182678236,"dividePrice":0,"high":0.06,"amplitude":0.016949,"preClose":0.059,"low":0.059,"week52Low":0.019,"pbRate":"10.24","psRate":"34.21","week52High":0.065,"institutionHeld":0,"latestPrice":0.059,"committee":-0.394229,"eps":-0.004944,"divideRate":0,"volume":1068139,"delay":0,"ttmEps":-0.004944,"open":0.059,"prevYearClose":0.025,"prevWeekClose":0.06,"prevMonthClose":0.06,"prevQuarterClose":0.033,"fiveDayClose":0.054,"twentyDayClose":0.062,"sixtyDayClose":0.033,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACW.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2020-10-19","symbol":"ACW.AU","defaultRemindTime":1603062000000,"type":"split","dateTimestamp":1603026000000,"forFactor":98,"toFactor":100,"ratio":0.98}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACW.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACW.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2593171285","title":"ASX Penny Stocks To Watch In December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2593171285","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593171285?lang=en_us&edition=fundamental","pubTime":"2025-12-22 03:01","pubTimestamp":1766343710,"startTime":"0","endTime":"0","summary":"As Australian shares experience a modest uptick, following Wall Street's lead, investors are keenly observing the market dynamics influenced by global economic indicators. Amidst these developments, penny stocks remain an intriguing area of investment, offering potential opportunities in smaller or less-established companies. While the term \"penny stocks\" may seem outdated, these investments can still provide value when backed by strong financials and growth prospects.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/8031000-choice2-main-header/1585186598236","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8031000-choice2-main-header/1585186598236"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/software/asx-apx/appen-shares/news/asx-penny-stocks-to-watch-in-december-2025-10","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-apx/appen-shares/news/asx-penny-stocks-to-watch-in-december-2025-10","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7061","CXL.AU","BK7045","BK7503","BK7067","BK7508","GWA.AU","BK7048","IGL.AU","EZZ.AU","BK7012","BK7077","FWD.AU","BK7055","BK7111","BK7128","EDU.AU","BK7132","BK7104","SSM.AU","BK7014","APX.AU","BK7506","BK7017","DSK.AU","MXI.AU","WAF.AU","AAL.AU","ACW.AU"],"gpt_icon":0},{"id":"2592099549","title":"BRIEF-Actinogen Randomizes 247th Patient in Xanamia Phase 2b/3 Alzheimer’s Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592099549","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592099549?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:33","pubTimestamp":1766064796,"startTime":"0","endTime":"0","summary":"BRIEF-Actinogen Randomizes 247th Patient in Xanamia Phase 2b/3 Alzheimer’s TrialDec 18 (Reuters) - Actinogen Medical Ltd ACW.AX:FINAL, 247TH PARTICIPANT RANDOMIZED AND COMMENCES TREATMENT IN ACTINOGEN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUAB1WPRG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","ACW.AU"],"gpt_icon":0},{"id":"2592906318","title":"Final, 247TH Participant Randomized and Commences Treatment in Actinogen’s Xanamia Pivotal Phase 2B/3 Alzheimer’s Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592906318","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592906318?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:00","pubTimestamp":1766062804,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUAB1WPRG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","ACW.AU"],"gpt_icon":0},{"id":"2592069529","title":"Actinogen Medical Ltd - Topline Final Results for Xanamia Trial in November 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2592069529","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592069529?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:00","pubTimestamp":1766062804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUAB1WPRG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACW.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2592400839","title":"Actinogen Medical Starts Treatment of Patients in Alzheimer's Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592400839","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592400839?lang=en_us&edition=fundamental","pubTime":"2025-12-18 09:44","pubTimestamp":1766022289,"startTime":"0","endTime":"0","summary":"Actinogen Medical  started treatment of all 246 patients in the XanaMIA phase 2b/3 Alzheimer's disease trial, and expects final results in November 2026, according to a Thursday filing with the Australian bourse.The company had earlier expected the results in the fourth quarter, the filing said.The trial will test whether the drug candidate Xanamem can slow the progression of Alzheimer's disease over 36 weeks in patients taking 10 milligrams of the drug or a placebo once daily, the filing added.An interim analysis of safety and efficacy futility from the partially completed trial will be conducted in January, the company said.The final analysis will compare the efficacy and safety of Xanamem with that of patients who received placebo, the company added.Shares of the company fell 2% in recent Thursday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","ACW.AU"],"gpt_icon":0},{"id":"2584616549","title":"Actinogen Medical Ltd-Acw CEO & CFO Present at Bell Potter Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2584616549","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584616549?lang=en_us&edition=fundamental","pubTime":"2025-11-19 06:37","pubTimestamp":1763505460,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUE2TP8ZD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ACW.AU","BK7508"],"gpt_icon":0},{"id":"2578711226","title":"Actinogen Medical Ltd-Acw Progress Update and Q&a Webinar Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2578711226","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578711226?lang=en_us&edition=fundamental","pubTime":"2025-10-28 05:48","pubTimestamp":1761601690,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nTUE4XS7SP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","ACW.AU"],"gpt_icon":0},{"id":"2577347509","title":"Actinogen Medical Ltd-Advance Notice Acw Progress Update and Q&a Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2577347509","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577347509?lang=en_us&edition=fundamental","pubTime":"2025-10-23 10:24","pubTimestamp":1761186259,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUEC2XK6K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","ACW.AU"],"gpt_icon":0},{"id":"2577310116","title":"Actinogen Medical Ltd-Acw September 2025 Quarterly Activity Report & Appendix 4C","url":"https://stock-news.laohu8.com/highlight/detail?id=2577310116","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577310116?lang=en_us&edition=fundamental","pubTime":"2025-10-23 06:20","pubTimestamp":1761171633,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nTUE1RHYTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","ACW.AU"],"gpt_icon":0},{"id":"2577489960","title":"Actinogen Medical Ltd-Acw CEO Presents at Canaccord Drug & Device Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2577489960","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577489960?lang=en_us&edition=fundamental","pubTime":"2025-10-21 05:52","pubTimestamp":1760997128,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nTUE74BS1Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","ACW.AU"],"gpt_icon":0},{"id":"2575220395","title":"BRIEF-Actinogen Medical Receives Initial A$5.5M Research And Development Tax Incentive Rebate","url":"https://stock-news.laohu8.com/highlight/detail?id=2575220395","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575220395?lang=en_us&edition=fundamental","pubTime":"2025-10-15 09:45","pubTimestamp":1760492717,"startTime":"0","endTime":"0","summary":"BRIEF-Actinogen Medical Receives Initial A$5.5M Research And Development Tax Incentive RebateOct 15  - Actinogen Medical Ltd ACW.AX:ACW RECEIVES INITIAL $5.5M RESEARCH AND DEVELOPMENT TAX INCENTIVE REBATEALL FIGURES IN AUDFurther company coverage: ACW.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nTUED6XRG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","ACW.AU"],"gpt_icon":0},{"id":"2575719228","title":"Actinogen Medical Ltd-Acw Receives Initial $5.5M R&D Tax Incentive Rebate","url":"https://stock-news.laohu8.com/highlight/detail?id=2575719228","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575719228?lang=en_us&edition=fundamental","pubTime":"2025-10-15 05:55","pubTimestamp":1760478934,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nTUED6XRG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","ACW.AU"],"gpt_icon":0},{"id":"2575228714","title":"Actinogen Medical Ltd - All Figures in AUD","url":"https://stock-news.laohu8.com/highlight/detail?id=2575228714","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575228714?lang=en_us&edition=fundamental","pubTime":"2025-10-15 05:55","pubTimestamp":1760478934,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nTUED6XRG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","ACW.AU","BK7067"],"gpt_icon":0},{"id":"2567111222","title":"Actinogen Medical Ltd. Achieves FDA Agreement for Streamlined Development of Alzheimer's Drug Xanamem","url":"https://stock-news.laohu8.com/highlight/detail?id=2567111222","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567111222?lang=en_us&edition=fundamental","pubTime":"2025-09-15 20:30","pubTimestamp":1757939429,"startTime":"0","endTime":"0","summary":"Actinogen Medical Ltd. has announced a significant milestone in its ongoing efforts to gain regulatory approval for Xanamem, a treatment for Alzheimer's disease. Following a Type C meeting with the US Food & Drug Administration , the company has reached a common understanding with the agency on the pathway to marketing approval. This includes agreement on regulatory starting materials, the design of an additional pivotal clinical trial, and the limited number of ancillary clinical pharmacology trials and nonclinical studies required. The FDA's approval of the planned program allows Actinogen to proceed with confidence, aiming for a future US marketing approval of Xanamem. The ongoing XanaMIA pivotal phase 2/3 trial is on track, with interim analysis expected in January 2026 and final results later that year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gene","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL52kTd6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210150020.SGD","LU2095319765.USD","BK4585","BK7067","IE00BKPKM429.USD","ACW.AU","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK7508","LU0314104364.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","NDAQ"],"gpt_icon":0},{"id":"2567489111","title":"Actinogen Achieves Agreement With the FDA in a Type C Meeting on the Manufacturing, Clinical and Nonclinical Activities Required for a Future US Marketing Approval of Xanamem for Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2567489111","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567489111?lang=en_us&edition=fundamental","pubTime":"2025-09-15 20:30","pubTimestamp":1757939400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nTUAC34YFN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ACW.AU","BK7508"],"gpt_icon":0},{"id":"2567323114","title":"Actinogen: FDA Agreed for Only One Additional, Pivotal Trial Using a Single 10 Mg Xanamem Dose Design VS. Placebo for Alzheimer's Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2567323114","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567323114?lang=en_us&edition=fundamental","pubTime":"2025-09-15 20:30","pubTimestamp":1757939400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nTUAC34YFN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","ACW.AU"],"gpt_icon":0},{"id":"2567114396","title":"Actinogen Medical Ltd - Meeting With European Medicines Agency for Alzheimer’s Disease Scheduled for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2567114396","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567114396?lang=en_us&edition=fundamental","pubTime":"2025-09-15 20:30","pubTimestamp":1757939400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nTUAC34YFN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACW.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2562745281","title":"Actinogen Medical Ltd. Announces Successful Xanamem Tablet Formulation Trial in Alzheimer's Treatment, Confirms Target Exposures","url":"https://stock-news.laohu8.com/highlight/detail?id=2562745281","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562745281?lang=en_us&edition=fundamental","pubTime":"2025-08-27 20:01","pubTimestamp":1756296063,"startTime":"0","endTime":"0","summary":"Actinogen Medical Ltd. Announces Successful Xanamem Tablet Formulation Trial in Alzheimer's Treatment, Confirms Target Exposures. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinogen Medical Ltd. published the original content used to generate this news brief via PR Newswire  on August 27, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nNDL1nCdP2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ACW.AU","BK7508"],"gpt_icon":0},{"id":"2562202912","title":"Actinogen Says Trial Results Indicate Target Therapeutic Dose for Alzheimer's Treatment Candidate Clinical Program, Shares Rise 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562202912","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562202912?lang=en_us&edition=fundamental","pubTime":"2025-08-26 14:10","pubTimestamp":1756188601,"startTime":"0","endTime":"0","summary":"Actinogen Medical  said that the results of a recent pharmacokinetics trial for the intended commercial tablet formulation of Xanamem, its treatment candidate for Alzheimer's disease, indicate that a dose of 10 milligrams once daily remains the target therapeutic dose for the clinical program, according to a Tuesday Australian bourse filing.The data supported the use of the 10 milligrams daily dose, irrespective of food intake, in the ongoing XanaMIA phase 2b/3 trial in people with mild to moderate Alzheimer's disease.16 individuals were studied in the trial on two occasions, one week apart. Each individual received a 10-milligram tablet of Xanamem once while fasting and once after a high-fat meal. Blood levels of Xanamem were measured frequently over the following 48 hours.The firm's shares rose 9% in recent trading on Tuesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACW.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2562145802","title":"Actinogen Medical - FY Net Loss Attributable a$14.7 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562145802","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562145802?lang=en_us&edition=fundamental","pubTime":"2025-08-25 16:43","pubTimestamp":1756111439,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nFWN3UH00O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACW.AU","BK7508","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}]}}